arrow-down arrow-left arrow-right check clock edit filter phone question-mark search submit-arrow

myTomorrows COVID-19 update.

Learn more

by myTomorrows myTomorrows | 20 Feb 2020

myTomorrows Collaborates with My Personal Therapeutics

AMSTERDAM, the Netherlands and LONDON, United Kingdom, 19 February 2020 - myTomorrows, a global, innovative health technology company, is pleased to announce a collaboration with My Personal Therapeutics, a London based biotechnology company looking to transform cancer care. Through this collaboration, myTomorrows and My Personal Therapeutics are working together to create awareness and facilitate access to emerging therapeutic options for patients with colorectal cancer.

 

Finding information about clinical trials and other treatment options when a family member or loved one has a life-threatening disease can be difficult. Guided by a patient-first approach, myTomorrows offers a single point of contact for patients suffering from a wide range of diseases such as cancer, blood disorders and rare diseases. When a patient or physician reaches out to myTomorrows, they can speak directly with a patient navigator who is part of myTomorrows’ medical team to get access to a personalised report listing all possible treatment options. In composing these personalised reports, myTomorrows uses artificial intelligence as the foundation for their proprietary knowledge database to search for emerging therapies worldwide making it easier for patients, their families and their physicians to explore treatment options. 

 

“We are extremely excited to announce this collaboration with My Personal Therapeutics. We share the vision of looking to transform cancer care, making information and treatment options more accessible for oncologists and their patients the world over,” said Michel van Harten, CMO of myTomorrows. “Our goal is for patients to have access to treatments that are most likely to work for them.”

 

My Personal Therapeutics was founded in 2018 in London by scientist and entrepreneur Laura Towart. Scientists and clinicians at the Icahn School of Medicine at Mount Sinai Center for Personalized Cancer Therapeutics (CPCT) in New York (USA) have taken a revolutionary new approach to cancer therapeutics. My Personal Therapeutics has exclusively licensed the Personal Discovery Process (PDP) technology in partnership with the CPCT for global commercialisation. PDP leverages Big Data and genomics to build personalised fruit fly ‘avatars’ that model individual patients at an unprecedented level of complexity. Using robotics, thousands of drugs are screened in combinations to identify drug cocktails designed to target the tumour while preserving the patient’s quality of life. 

 

“myTomorrows and My Personal Therapeutics share a commitment to using technology to enable scientific discovery and to help patients access emerging therapeutic options and regimes,” said Laura Towart, CEO of My Personal Therapeutics. “Our collaboration with myTomorrows will help us reach more colorectal cancer patients and their oncologists and match them with potential treatments.” 

 

Contact Details

 

myTomorrows

Michel van Harten, Chief Medical Officer

Phone: +31 88 5253 888

Email: medical@mytomorrows.com

 

My Personal Therapeutics

Laura Towart, Chief Executive Officer

Email: laura@mypersonaltherapeutics.com

 

About Expanded Access Programs 

An Expanded Access Program (EAP), also known as Managed Access Program, supports in a compliant and controlled way, treatment with a medicine currently not licensed for that indication in a patient’s country of residence. Such treatment can be an option for patients who are in high unmet medical need and have exhausted all registered treatment options and are not eligible to participate in a clinical trial.

 

About myTomorrows 

myTomorrows operates as a two-sided platform. It serves the interests of both patients and healthcare professionals, as well as drug development. On one side, the company provides information on all treatment options to patients and physicians when registered treatments have been exhausted. On the other side, myTomorrows is specialized in expanded access regulations and administration and real-world data collection, evolving scientific clinical development. myTomorrows has gained experience in running over 30 EAPs over the past 5 years, in more than 40 countries worldwide. For more information, please visit www.mytomorrows.com. For enquiries about myTomorrows or Expanded Access, please contact our medical team via medical@mytomorrows.com.  

 

About My Personal Therapeutics

My Personal Therapeutics, a London based biotechnology company offers personalised cancer therapeutics utilizing comprehensive, genomics-based drug screening technology developed at and commercialised in partnership with the Icahn School of medicine at Mt Sinai Medical Center.    

 

The Personal Discovery Process (PDP) is effectively a massive clinical trial for a single patient. Scientists at My Personal Therapeutics engineer the genetic complexity of each patient’s unique tumour network into an army of 400,000 fruit fly ‘avatars’. Using robotics, evaluating up to 1,600 FDA approved drugs including non-cancer drugs, to identify drug combinations designed to treat the tumour itself. My Personal Therapeutics is integrating predictive modelling and artificial intelligence to enable rapid and affordable treatment recommendations.